MUMBAI, February 15, 2013 /PRNewswire/ --
Bharatbook.com is pleased to announce a new research report on Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors (http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html)
New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years. This report highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors, the clinical data and competition.
(Logo: http://photos.prnewswire.com/prnh/20130128/590935 )
Key Points Discussed in the Report
PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)
Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)
BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)
SymBio pharma (4582, ¥488)
Curis (CRIS, $2.99)
Gilead (GILD, $40.36)
Pharmacyclics (PCYC, $69.28) -
Infinity pharma (INFI, $35.02)
Request for Sample pages - http://www.bharatbook.com/RequestSample.asp?pid=372901
Table of Contents
Executive Summary
Drugs in the Pipeline
Phosphoinositide 3-Kinases (PI3Ks) inhibitors
Scientific Rationale
Dual inhibitors
Bruton's Tyrosin Kinase (BTK) Inhibitors
Scientific Rationale
BTK inhibitors - Pipeline
M&A to Follow - Kinase inhibitors have attracted partnering deals at a premium
Kinase Inhibitor: Select M&A / Deals
Upcoming Milestones Related in 2013-14
Combination Studies - PI3K, BTK + Rituxan/ Bendamustine
Idelalisib (GS-1101) - Clinical Data
Rigosertib - Clinical Data
Other PI3K or Dual Inhibitors - Clinical Data
Combination Studies of PI3K and BTK Inhibitors
Ongoing Trials of PI3K and BTK Compounds
Company Analysis
Curis (CRIS) -
Gilead -
Infinity Pharma
Pharmacyclics
SymBio
Get an overview of the report at or request for sample pages at -
For Complete range of Related Reports:
About Bharat Book Bureau
Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.
Contact us:
Maria
Bharat Book Bureau
India: +91-22-27810772, 27810773
USA/Canada - 1-866-279-8368 (Toll free)
Skype - bharatbook
E-mail: maria@bharatbook.com
Website: http://www.bharatbook.com
Share this article